Potent LDL cholesterol lowering effects, ‘good’ HDL unaffected.
ezCOL BV was established in the ESA Business Incubator
No adverse effects observed
We strive to provide patients with elevated cholesterol with a new intervention modality that potently lowers their blood plasma LDL-cholesterol (the 'bad' cholesterol) to the most optimal target values without the adversity that is commonly observed with current therapeutics. As such, ezCOL aims to develop a best-in-class LDL-lowering drug with the lowest possible adversity.
In our vision, our ezCOL product becomes the class-leading cholesterol-lowering drug with lowest adversity and at affordable costs. This way ezCOL BV can leave a positive footprint on society, by lowering societal burdens, ensuring an effective and affordable healthcare system and providing maximal patient comfort and carefree living.